Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma. Canadian Hematology Today, Toronto, Canada, v. 1, n. 1, p. 38–42, 2022. DOI: 10.58931/cht.2022.1110. Disponível em: https://canadianhematologytoday.com/article/view/1-1-6-peters. Acesso em: 11 sep. 2026.